A change of therapeutic focus, a full rebrand and a major cash injection will shake things up considerably at Massachusetts, USA-based Cullinan Therapeutics. 17 April 2024
Japanese drugmaker Astellas expects to book an impairment charge of 70 billion yen ($453 million) in the fourth quarter of Japan’s 2023 fiscal year, which ended 16 April 2024
US immuno-oncology company Portage Biotech has around a fifth of its stock market value since early Friday, when the firm reported that it is expanding its eval 15 April 2024
Roche’s CD20xCD3 T-cell engaging bispecific antibody Columvi (glofitamab) has met the primary endpoint of overall survival in relapsed or refractory diffuse la 15 April 2024
Data from the RESMAIN study of Kinselby (resminostat) have been presented at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasaden 11 April 2024
Los Angeles-based TORL BioTherapeutics, a biotech focused on discovering and developing antibody-based immunotherapies, has closed an oversubscribed $158 millio 10 April 2024
A private share placement is set to land Massachusetts, USA-based Acrivon Therapeutics with an additional $130 million to fund its oncology research. 10 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.